Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04745403 | Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)(SAFE-T-HBV) | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05444478 | Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma | recruiting | N/A | 274 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05951231 | Liver Transplantation After ex Vivo Liver Perfusion(EVOLVE) | not yet recruiting | N/A | 22 | Oslo University HospitalOTHER | 0 | Nov 1, 2023 | clinicaltrials |
| NCT06096896 | The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study | active not recruiting | — | 334 | Shandong Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06044506 | Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma | recruiting | Phase 1 | 3 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04616495 | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases(TRASMETIR) | recruiting | — | 30 | Hospital Universitario La FeOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05994859 | SIRT for Potentially Resectable HCC | recruiting | N/A | 35 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05047510 | GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma | recruiting | N/A | 60 | Chinese Academy of SciencesOTHER_GOV | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05502198 | Relevance of Sarcopenia in Advanced Liver Disease(ACCESS-ESLD) | recruiting | — | 150 | Linkoeping UniversityOTHER_GOV | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05433701 | Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC | active not recruiting | N/A | 178 | Jonggi ChoiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05971628 | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma(RAPID-HCC) | not yet recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05926726 | GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT03347162 | Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer | active not recruiting | — | 1,000 | Rigshospitalet, DenmarkOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05896956 | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | not yet recruiting | — | 500 | RenJi HospitalOTHER | 0 | Jun 9, 2023 | clinicaltrials |
| NCT05887505 | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy | not yet recruiting | N/A | 120 | Taoyuan General HospitalOTHER_GOV | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05870969 | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)(dSEARCH) | recruiting | — | 20,000 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05203120 | A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04556214 | Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial) | recruiting | N/A | 15 | Oslo University HospitalOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05752890 | A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma | not yet recruiting | — | 95 | National Taiwan University HospitalOTHER | 0 | Mar 3, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05738980 | Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3 | recruiting | N/A | 88 | Beijing HospitalOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05602974 | Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study | not yet recruiting | N/A | 140 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718492 | A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents | recruiting | N/A | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | recruiting | Phase 4 | 24 | The Methodist Hospital Research InstituteOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04442334 | The European NAFLD Registry | recruiting | — | 10,000 | Newcastle UniversityOTHER | 12 | Jan 6, 2023 | clinicaltrials |
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05644743 | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | not yet recruiting | — | 40 | Chengjun Sui,MDOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT05331911 | Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors | recruiting | Phase 4 | 500 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05620706 | Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04078230 | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | recruiting | N/A | 168 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Nov 9, 2022 | clinicaltrials |
| NCT05608213 | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC | recruiting | Phase 3 | 187 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05541601 | Prospective Cohort for Early Detection of Liver Cancer(Pearl) | recruiting | — | 3,000 | University of OxfordOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05534906 | The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) | recruiting | — | 250 | University of OxfordOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04946773 | Deep Liver Phenotyping and Immunology Study(DELPHI) | recruiting | — | 100 | University of OxfordOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05240950 | Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases | recruiting | Phase 1 | 18 | Changhai HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Nov 18, 2023source: clinicaltrials